Eurofins A global leader in bioanalytical testing in the food, - - PowerPoint PPT Presentation

www.eurofins.com

Eurofins

A global leader in bioanalytical testing in the food, environment and pharmaceutical sectors

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

1

Debt Investor Presentation January 2015

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

2

Disclaimer

The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement

• f Eurofins Scientific’s management and involve risks and uncertainties including, but not limited to, risks associated with the

inherent uncertainty of research, product/ service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation

• r intention to release publicly any updates or revisions to any forward looking statement or estimate.

In addition, Eurofins provides in the Income Statement certain non-IFRS information (“Adjusted Results and Separately Disclosed Items”) that excludes certain items because of their nature and the impact they have on the analysis of underlying business performance and trends. (Please refer to description of these terms in the Company’s Annual Report). The management believes that providing this information enhances investors' understanding of the company’s core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever. Analyst forecasts quoted are based on published analyst views. They are the responsibility of the investment banks which publish those forecasts and should not be interpreted as representing the views or expectations of Eurofins Scientific or the Eurofins Scientific management. In particular, they do not constitute a profit forecast or estimate or trading statement by Eurofins Scientific S.E. Similarly, objectives presented are only objectives and may not be achieved in reality, potentially by a wide margin, due to a variety of factors.

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

3

Introduction Market & Strategic Positioning Finance & Outlook Transaction Overview Summary Appendix

Contents

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

4

Eurofins’ Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis Founded in 1987 IPO in 1997 in Paris at EUR 1.83 per share Network of more than 200 laboratories in

36 countries

Over 100,000 reliable analytical methods Over 16,000 employees Simplified shareholder structure: Martin

Family 42.7% of share capital (59.5% of voting rights); Free float 57.3%

Key figures 2013 2008-2013 CAGR Revenues EUR 1,226m 14% EBITDA EUR 189m 19% Net Profit EUR 72m 32%

*Adjusted– reflects ongoing performance of the mature and recurring activities excluding “separately disclosed items”

Food Environment Pharmaceuticals

Eurofins provides testing services in three main areas that have a strong impact on human health:

“Recent trends in global food production, processing, distribution and preparation are creating an increasing demand for food safety research in order to ensure a safer global food supply.” World Health Organisation

EUROFINS 2017: Mid Term Objectives

EUR 2bn Revenues (13% CAGR from 2013) >20% Adjusted EBITDA Margin

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Market size estimate

~ EUR 4bn

*To the best of Eurofins’ knowledge, based on data available to the Group

~ EUR 2.0bn ~ EUR 5bn N°1*

worldwide N°1 to N°3* worldwide

Testing for Testing for Testing for Testing for Pharma/ Pharma/ Pharma/ Pharma/ Biotech Biotech Biotech Biotech Environment Environment Environment Environment Testing Testing Testing Testing Food & Food & Food & Food & Feed Feed Feed Feed Testing Testing Testing Testing N°1*

worldwide

Eurofins ranking

N° 1 in Europe N° 1 in Germany N° 1 in France N° 1 in Scandinavia N° 1 in Benelux N° 1 in the UK** N° 1 in Brazil N° 2 in the USA** N° 1 in Agri Testing EU N° 1 in Europe N° 1 in Germany N° 1 in France N° 1 in Scandinavia N° 1 in Benelux N° 1 Worldwide in Pharma Product Testing N° 1 Worldwide in Discovery Pharmacology Services Among top 3 global providers

• f central laboratory, genomic

and agrosciences services N° 1 or 2 in most segments/ countries in Europe

** except routine Bacteriology - focus on high end analysis

Leading global and local market positions

New! New!

5

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

6

Demand for safe pharmaceuticals, quality food and clean environment Risks linked to global sourcing and brand vulnerability Consolidation of the fragmented laboratory market and scale effects

Drivers for long-term market growth

Outsourcing of internal laboratories by industry One-stop shopping (focus on few global testing suppliers) Increasing wealth and quality of Life Technological progress Advancing globalisation New analytical methods and lower detection limits Consumer expectations for protection

Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

7

An international network of world class, standardised laboratories is attractive for our customers

80% of the world’s population still has limited access to testing laboratories

• N. America

22.7% Germany 17.5% France 17.0% Others 14.6% Nordic Region 11.9% Benelux 10.9% UK & Ireland 5.4% H1 2014 revenue split :

Entry into high-growth markets with start ups & acquisitions

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

8

Strong growth fueled by market growth, share gains and acquisitions

* Company objective

• 200

400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014* 2017*

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

CAGR 10yrs 22% CAGR 5yrs 14% REVENUES EUR m

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

9

On track towards 2017 objectives

Eurofins 5 year Report Card: 2008-2013 CAGR

Achievements in 2013 Over 6.5% organic growth versus 5% objective 24% increase in adjusted EBITDA More than 10 acquisitions with combined revenues of ca. €120m 26% increase in operating cash flows

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

2014: second year of our 5-year journey

9M 2014 18.6% revenue increase in Q3 to EUR 370m brings revenues for 9M 2014 to over EUR 1 billion, a 14.9% increase from 9M 2013, over 6%

• f which was organic (over 8% excluding

companies in significant restructuring). 14 acquisitions in 9M 2014 for total annualised revenues in excess of EUR 150m. Sustained operating momentum in the group’s largest markets HY 2014 17% increase in adjusted EBITDA, translating to 60bp margin expansion in H1 2014 Stable profits despite peak in one-off costs YTD 2014 On track to deliver ca. 40,000m2 of the 100,000m2

• f modern lab surface planned between 2014-

2016 by the end of this year. Entry into specialised, genomics-based diagnostic testing market via the acquisition of ViraCor-IBT*

*Acquired on 01 July, 2014

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

10

Eurofins’ strategy aims at building long lasting competitive advantages Extensive expertise in local regulations for all

major markets, and one-stop contact for compliance in multiple countries

Globally reliable standards of high quality and

consistency

International key accounts management Internet-based transactions and access to

testing results

Competence Centres & R&D activities Proprietary technologies for proof of

• rigin, virus phenotyping & authenticity

testing

Continuous development/acquisition of

advanced technologies

One stop shop Leading technology Pure-play laboratory operator

International network with a presence in

36 countries

Vast technological portfolio with more

than 100,000 reliable methods

Over 100 million assays performed per

year

But one contact person for each

customer

Industrialised processes Unrivalled expertise accessible to all

customers

Continually expanding geographical coverage Proven operating model that can be rolled-out

in various/multiple markets

Quality of customer service

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

11

Introduction Market & Strategic Positioning Finance & Outlook Transaction Overview Summary Appendix

Contents

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

12

Consumers’ increasing awareness and demand for safe and high quality food

The Food testing market has robust growth drivers

Compels industry to strengthen its testing programs New products (GMOs, new packaging, etc.) create need for new tests Governments increase regulations on food control Brands have become more global and vulnerable to contaminations Transparency and traceability are becoming the priorities Increasing pressure on producers and manufacturers to invest in testing

Food scares and crises, widely covered in the media

Demand for a high quality, state-of-the-art, international network of laboratories

Globalisation: Raw materials sourced from countries with different QC practices Outsourcing of industry’s internal or state-

• wned

laboratories

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

13

Retail & Distribution

Eurofins’ Food & Feed testing offering is the most comprehensive in the market

Agricultural production, product development Production

Dioxins Veterinary drug residues Organic residues POPs Heavy metals Irradiation Quality Control Vitamins GMO Labelling Purity Nutritional Microbiology Sensorial Authenticity Pesticides Mycotoxins Allergens

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

14

Year Brand/ Contamination Impact Cost Country Salmonella in tomatoes and peppers

2008

• E. Coli in

cookie dough 70 people sick, 25 people hospitalized, job losses, withdrawal of 86 million "cookies-worth”, court proceedings initiated 50,000 infants ill, 6 deaths, global recall of dairy and related products, criminal charges in China Melamine in dairy products Sanlu/ Fronterra + global brands

~ USD 100-

250m

Unquantified

2009

About 1,500 people sick throughout US & Canada – pulling of products from shops & restaurants

2008

Nestlé North America/ Mexico Dioxins Recall of Irish pork products, job losses, destruction of 100,000 pigs

2008

FreshPlaza CNN Health BBC News

Irish pork

> EUR 300m

Irish Exporters Association

Salmonella in peanut butter

2008

~ USD 100m

• Est. only for

Kellogg’s 9 dead, 683 people sick, global recall of peanut butter and related products (1,600 types of products involved) Kellogg’s, Unilever, General Mills

Bloomberg

High profile food scares have expensive consequences for producers…

Dioxins in eggs, poultry and pork About 3,000 tons of feed contaminated with oil intended for use in bio-fuels, 4700 farms closed, revenues lost, tightening regulation

2011

Germany

BBC news

Beef products contaminated with horse meat Sales of frozen burgers plunged 43% and frozen ready meals fell 13% in the UK between 21 Jan – 17 Feb, 2013, at the height of the scandal

2013

Europe

The Guardian

~ EUR 360m

Market value lost for Tesco

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

15

…and destroy market value

48% drop in share price in first week. Threat of multiple law suits. Over 100 brands & over 60m cans of recalled product. The largest customer (11% of sales) has suspended orders (thought to be WalMart). Direct cost estimated at US$ 42m

2007 example: Menu Foods is the largest maker of wet cat and dog food in N. America

Melamine contamination of pet

foods due to illegal use of a plasticiser in wheat and rice gluten raw material supplies from China.

Tens, possibly hundreds of pets died

• 48%

In the wake of the scandal drop in orders resulting in a $3.6m loss in the Q2 vs a $2.6m profit in Q2/2006

• 44%

Source: http://www.lapresseaffaires.com

Contamination Direct impact Indirect impact

In fact, this was the same type of contamination to affect baby milk

• ne year later.

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

16

Horsegate: A reminder of the need for more systematic testing

Horsegate Timeline

Dec 2012 Irish authorities become aware of the adulteration in ABP Food Group burgers with 29% horse meat content Jan 2013 Eurofins Germany confirms to FSAI presence of horsemeat on samples tested from Tesco, Asda, Iceland, etc. Tesco market value declined EUR 360m* Feb 2013 EU Commission launched coordinated control testing for presence of horse DNA and phenylbutazone. Mar 2013 Of the 4,144 tests done to detect horsemeat, 193 tested positive (4.7%) Of the 3,155 tests done to detect phenylbutazone residues, 16 tested positive (0.5%) Large food manufacturers and retailers caught up in the scandal identified weaknesses in their supply

• chains. The official results confirm that only a

sufficient level of SYSTEMATIC TESTING across the food supply and production chains can reduce risk and prevent similar scandals

http://ec.europa.eu/food/food/horsemeat/timeline_en.htm http://en.wikipedia.org/wiki/2013_meat_adulteration_sca ndal#cite_note-idsum-55 EU Commission Wikipedia * The Independent, 16 January 2013

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Eurofins’ response to aid the industry

Rapid capacity scale-up by allocating more of its DNA-testing resources to food analysis, and in particular, meat speciation Launch of relevant meat speciation and contamination test-packages Industry-beating accuracy and Turn-Around- Time (TAT) Developed new protocols based on the latest Next Generation Sequencing (NGS) technologies to increase its DNA-testing capacity and significantly reduce the cost per analysis. Eurofins reduced its prices for DNA analysis for meat testing during the crisis to reduce the cost to allow the industry to not only comply with regulations, but systematically manage the risks in their supply chain.

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

17

Eurofins is meeting the demands of global players

The largest global food & beverage producers and retailers are clients of

Eurofins Food and Beverage Retailers

2013 Sales in EUR billion 2013 Sales in EUR billion

Nestlé

Switzerland

74.9 Unilever

UK /Netherlands 49.8

PepsiCo

USA

48.8 Coca-Cola

USA

34.4 Mars*

USA

25.0 Danone

France

21.3 McDonalds

USA

20.6 Kraft Foods*

USA

13.4 Kelloggs

USA

10.9 Pernod Ricard

France

8.6

* estimates

Wal-Mart Stores

USA

347.6 Carrefour

France

84.3 CostCo

USA

77.3 Tesco

UK

76.3 Kroger

USA

72.3 Metro AG*

Germany

65.4 Aldi*

Germany

57.0 Lidl*

Germany

56.7 Casino Guichard

France

48.6 ITM Enterprises

France

39.9

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

18

The Pharma testing market is both healthy and full of potential

The increasing complexity of clinical trials leads to increasing

amounts of diagnostic procedures performed per patent

Regulatory bodies (e.g. FDA) are demanding more study data to

improve safety

Clinical trial processes are becoming increasingly rigorous to

ensure drug efficacy

The spend per drug trial is rapidly increasing

Need for big pharma companies to expand new drugs pipelines Rapid technological change & increasing complexity in testing require ongoing investment in technology & expertise

Greater trial complexity & size will increase likelihood of using CROs

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

19

Underlying trends are in tact for continued growth Large pharmas need to refill their product

pipeline as the ‘blockbusters’ start to come

• ff patent

Drug development expenditures have

increased substantially in recent years

Total R&D is over USD 120bn and is

expected to further increase

Sponsors outsource drug development to:

• Reduce their fixed cost base
• Access competencies that they do not have in-house
• Access experience and regulatory expertise in new

geographies

Growth of biotechnology industry:

• Limited physical infrastructure
• Lack of internal expertise

Source: Citigroup Research 18 Feb, 2014 Source: Citigroup Research 18 Feb, 2014

Global Drug R&D Spending (US$ bn)

Total R&D Spend $ 140 bn Portion that could be

• utsourced

$ 80bn Currently Outsourced $34bn

Global % R&D Outsourced

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

20

Eurofins Pharma Services: 6 activity groups

Genomics Discovery Pharmacology Pre-clinical / Early Development Clinical (Central Laboratory) Pharma Products Testing / cGMP QC Registration

Sequencing Oligonucleotides Pharmacogenomics Transcriptomics Genotyping SNP-analysis Pharmacology Bioanalytical analysis Translational medicine Phase I studies Biomarkers Bioanalysis Immunogenicity Proteomics Microbiological and Anti-infective analysis Bioavailability Bioequivalence Impurities Analysis Stability Studies Process development Hygiene Monitoring Packaging analysis Regulatory/Biocides/ Chemicals/Agro- chemicals/ Ecotoxicology/ Registration/ REACH... Phases I - III Registration Phase IV, Surveillance, Quality Control Basic Research, Discovery, Combinatorial, Biological Product Libraries, etc Pharmacology, Exploratory Toxicology, PK, Metabolism, etc High-throughput- screening Molecular- pharmacology cell-based assays in vitro screening in vitro profiling in vivo safety in vivo efficacy

Spanning the entire drug development cycle

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

21

The Top 10 largest global pharmaceutical companies are all clients of Eurofins

Top 10 pharma companies Pfizer Sanofi Aventis GlaxoSmithKline Novartis AstraZeneca Merck & Co Johnson & Johnson Roche Eli Lilly & Co Bristol-Myers Squibb Country USA France UK Switzerland UK USA USA Switzerland USA USA Global CRO Market

USA 60% Europe 20% Japan 8% Rest of World 12% Market Breakdown CAGR* 12% 9% 18% 14%

Source: William Blair &Co. * 2007 – 2012est.

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

22

Increasing demand by citizens for a clean environment EU expanding regulation (e.g. REACH) Increasingly long list of products identified as toxic Requirement for more sophisticated analyses and more

expensive equipment The Environmental testing market continues to grow

Rise in contamination & pollution issues Progress in epidemiology & medicine has identified more compounds as toxic

Compels industry to increase testing and outsource internal labs

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

23

• Outdoor pollutants
• Indoor and ambient

pollutants

Eurofins serves all the main environmental testing markets

SOIL AIR WATER Eurofins is the No.1 environmental testing service provider in the world*

Drinking water and groundwater

analysis

Full range of contaminants Analysis of soil for full

range of contaminants Consulting and sampling companies are natural partners Lancaster Environmental Testing is the laboratory

• f choice for Fortune 500

companies in the USA

* Management estimate based on available information

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

24

Global trends in regulation support the business

Strong regulated markets (EU, USA) are still amending and adding regulations Eastern European rules catching up with EU Fast development of regulation in Asia Regulation used for support of trading blocks (e.g. EU, NAFTA, ASEAN) European Food Regulation (EC)178/2002

Recently passed

European REACH directive US Country of Origin Labelling (COOL) law PRC Food Safety Law in China Food Safety Modernization Act (FSMA) in

USA In the pipeline

Comprehensive Review of Food Labelling

Law and Policy in Australia & New Zealand

Food imports Labelling (e.g. allergen, origin label,

reference intakes)

Foodstuffs (marketing standards for

beverages, meat, fish, dairy products)

Pesticides GMO & GM products Additives (vitamin & mineral fortification,

flavourings, sweeteners, enzymes) Key areas of food regulation Major pieces of legislation

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

25 *Registration Evaluation and Authorisation of Chemicals(1): Regulation (EC) N° 1907/2006 and Directive 2006/121/EC of the European Parliament and of the Council

Metals, resins, acids, solvents, oils, fibres in textile, car components, toys, cosmetics, plastics, rubber, microchip, etc. Food and drug ingredients are excluded

EU regulations a key driver for the testing industry – e.g. REACH directive Listing and assessing the safety of 30,000

chemical substances used by industries in Europe over 11 years

Replacing the most dangerous ones - no

chemical safety studies were conducted before 1981; only 3700 new chemicals analysed up to 2008 out of 100,000 used currently in EU Time line

Physico-chemical properties: density, viscosity, etc. Toxicity: skin, eye, mutagenicity, inhalation, oral, reproductive Ecotoxicity: invertebrates, plants, fish, birds, soil, water, degradation

Increasing testing requirements from 2010 Objectives Examples of affected products or industries Type of testing Estimated cost EUR 10bn according to the EU including EUR 1.5bn for testing over 11 years

> 1 t/ p.a. production > 100 t/ p.a. production > 1,000 t/ p.a. production + substances of very high concern Nov 2010 May 2013 May 2018

Deadlines for registration

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

26

Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins

Danish Hydrology Inst. Official water reference lab Scandinavia Suez/Sita Envirolab The Netherlands Danish farmers association Steins’ water/environment laboratory Denmark Southern Water Water testing laboratory UK Lyon University Hospital Phase I Activity France Austrian Research Institute Food testing Austria Clermont University Mineral water analysis France Raisio Group Food product testing Finland Mondi Environmental, paper/pulp testing Slovakia DLG Group Food and feed producer Denmark Miljølaboratoriet Environmental testing network Denmark BASF/QTA Environmental, chemicals USA MWH Global Environmental, water-testing USA TÜV SÜD Dioxin Analysis Germany Cranswick plc Food testing UK Danone Infant and clinical nutrition analysis Germany

Company Outsourced Activity Country

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Laboratory Network Investments (1/2): Greenfield projects in high-growth markets

Food Food, Pharma, Env Env Food Ireland Spain Portugal Netherlands Food, Pharma Pharma, Food Food, Pharma Food Brazil Food Agroscience Food Agroscience Agroscience Poland Hungary Czech Republic Bulgaria Romania China India Japan

India: Food Lab profitable in year 2 of start-up Japan: Radioactivity lab set up; and profitable in year of establishment. Strong start in Environment testing Brazil: Food Testing profitable; Microbio MAPA audit passed Eastern: New labs in CZ Republic and Europe Poland Ireland: Through Lancaster acquisition market leadership position in PPT1 reached France: Through IPL acquisition market leadership position reached in Environment & Water testing Eurofins’ start-up businesses in aggregate became profitable in 2013

Operational achievements

Country Market Europe Americas Eastern Europe Asia

27

1 Pharma Product Testing

US Food - Microbiology

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Laboratory Network Investments (2/2): Expand / modernise laboratory sites

80 new/expanded modern state-of-the-art sites to enable consolidation /

closure of smaller or old sites

Total of ca. 240,000 m2 added or brought to most modern standards

between 2005 – 2013 (40,000 m2 in 2013 alone)

100,000 m2 of additional modern laboratory surface planned for 2014-2016,

• f which over 40,000m2 planned to come on stream in 2014 alone

Kalamazoo Vallensbaek Hamburg Les Ulis Saverne Acton Singapore

2006 - 2008 2009

Holsterbro Lidköping Rotterdam Cuneo Washington Huntsville Suzhou Nantes Denver Princeton Vejen Malbork

Major facilities : new or recently upgraded and planned for 2014-2016

Niefern Ebersberg Sao Paolo

2010

Cologne Barneveld Des Moines Shanghai Shenzhen Tokyo Nantes (Micro) Ebersberg ext.

2011

Wolverhampton Saverne, FR ext. Glostrup, DK Melbourne, AU Monrovia, CA Garibaldi, BR Mikkeli, FI

2012 2014-2016

Romsey, UK Freiberg, DE Hamburg, DE ext. Reichenwalde,DE Vejen, DK ext Uppsala, SE Bangalore, IN New Orleans, LA Louisville, KY

• St. Charles, MO

Aix-en-Provence, FR Nantes, FR ext Saverne, FR ext Douai, FR ext Les Ulis, FR ext Moss, NO Dungarvan, IE ext Lancaster, PA ext. Auckland, NZ ext Yokohama; JP ext Hamburg, DE ext. Lancaster, PA ext. Seattle, WA Vergeze, FR ext. Graauw, NL Wageningen, NL

2013

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

28

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Market Share: Eurofins is the leader in its industry – and we continue to reach new market leadership positions

New Markets

= Market Entry

Denmark: Food and Env. Brazil: Food Testing France Environment USA: Pharma Products Testing Sweden, Norway: Food and Env. Europe: Agroscience, Genomics Japan: Genomics Italy, Poland, Austria, Slovakia Agri Testing Europe Hungary, Finland China, India, Singapore, Japan Environment Australia, New Zealand Global: Discovery Pharmacology

X

No 1

2001 2002 2003 2004 2005 2006 2007 2008

Eurofins already has long-standing no.1 or no.2 positions in its main markets: Germany (Food + Env.), France (Food), Benelux (Food + Env. + Central lab)

2009 2010 2011 2012

No 1

X

No 1

X

No 1

X

No 1

X

No 1

X

No 1

X

No 1/3

X X X

2013

X X

No 1

X X

No 1

2014

29

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

30

Eurofins’ strategy builds high Barriers to Entry

• GLP
• GMP
• GCP

ISO 9001 ISO 17025 FDA Approved

Offering a premium quality service … ... and leveraging internal efficiencies

Portfolio: over 100,000 reliable methods –

unique in the world and ahead of competition

Global laboratory network: fully set up for

cross-selling worldwide to customers

Accreditations: multiple international

accreditations

One-stop shop: single point of contact for

compliance to regulations of many countries

Standardised testing in 36 countries Sales and marketing: international teams

plus dedicated key account management

Reputation: high standards of quality and

consistency - the Eurofins brand

Internet: web-based transactions and

• nline access to testing results increase

switching costs

Industrialising the laboratory process:

rationalisation of sites and personnel

Competence Centres: high volume

laboratories providing highest levels of expertise and service

Technology: the latest available in the

market providing the most accurate results

Economies of scale in Group purchasing

and sales functions

IT systems: cross-Group information tools

and standardised production systems

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

31

Introduction Market & Strategic Positioning Finance & Outlook Transaction Overview Summary Appendix

Contents

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

32

Start-ups: 17 start ups

between 2006 and 2010

Typically losses in years 1

and 2 of about EUR 1-2m p.a. per start-up

Initial Capex EUR 1- 3m per

lab (e.g. premises, equipment)

Upgrade existing

laboratories: ca. EUR 440m invested in additional capital in 2006-2013

Heavy investment in new markets and resources for future profits

Deploy IT systems

eLIMS, eCommerce (EOL)

Best practice lab

• rganisation & processes

Consolidation into large,

world-class sites

Standardised testing

procedures

Invest in state-of-the-art

technology

Under development perimeter Bringing recently acquired labs to group standards Building corporate resource for future size and growth

Recruitment of top

leadership

Additional layer of

management to lead global business lines

Central IT systems and

processes

(e.g. ERP, CRM)

Additional central cost

+EUR 13m 2010 vs 2005 +EUR 13m 2013 vs 2010

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

33

Selective acquisitions to consolidate and secure leadership of our markets

Lancaster Laboratories (US, Europe, 2011) IPL (France, 2011) Nihon Kankyo (Japan, 2012) Pan Labs (US, 2012), Cerep (France, 2013) and DDS Millipore (US, 2014) NZ Labs (NZ, 2012) and mgt-Labmark (Australia, 2013) Danone CLF (Germany, 2013) Applus Agrofood Testing (Spain, 2014) ViraCor IBT (USA, 2014) Anatech (Brazil, 2014)

• Global market leadership in pharma products testing
• Leading position in water testing in France
• Leading position in environment testing in Japan
• Create world leader in Discovery Pharmacology
• Strengthen Asia Pacific footprint
• Outsourcing for infant nutrition analysis, demonstrating

Eurofins capabilities

• Leading position serving the Spanish food & retail industry
• Leveraging Eurofins’ genomics testing capabilities to expand

into new market segment

• Reinforces Eurofins’ footprint in one of the world’s fastest-

growing environmental testing markets

Selected recent transactions Rationale/impact

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

In 2013: >10 acquisitions with annual turnover ca. EUR 120m In 9M 2014: 14 acquisitions with annual turnover > EUR 150m

On 8 December 2014, Eurofins has signed a definitive agreement to acquire Boston Heart Diagnostics Corporation (closing expected to occur early 2015)

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

34

Positive trends drive solid operating results

Adjusted – reflects the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. LTM – last twelve months Separately disclosed items – includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects.

HY 2014 HY 2013 +/- % Adjusted Results EURm Adjusted Results Separately disclosed items Statutory Results Adjusted Results Separately disclosed items Statutory Results Revenues 643.5 643.5 570.3 570.3 12.8% EBITDA 109.0

• 18.0

91.0 93.1

• 14.8

78.2 17.1% EBITDA Margin (%) 16.9% 16.3% 60 bp EBITAS 76.3

• 23.0

53.2 66.2

• 19.4

46.8 15.2% Net Profit 48.9

• 26.3

22.6 45.2

• 22.7

22.5 8.28% Basic EPS 3.24

• 1.75

1.50 3.02

• 1.52

1.51 7.3% Capex 56.9 43.0 32.4%

• Op. Cash Flow

47.4 54.7

• 13.3%

Net Debt 485.7 381.5 27.3% Net debt/ LTM Adjusted EBITDA 2.07x 1.94x NA

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Growth and Profitability are critical objectives

3-tiered margin support towards

mid-term profitability objective

1. Start of profit contribution from start-ups 2. Proportion of companies in restructuring becoming smaller compared to the size of the Group (11.7% of total Group revenues in H1 2014 versus 12.3% in H1 2013) 3. Investments in large industrialized laboratories unlock operational leverage

A target “cruising altitude” of >20%

adjusted EBITDA margin, in addition to top line growth should ensure continued earnings and cash flow growth

35

Group Profitability Objectives++

*E – company objectives ++ Based on stated company objectives and assumes linear acquisitions 2013-2017

10% 12% 14% 16% 18% 20% 22% 500 1,000 1,500 2,000 2,500 2011 2012 2013 2014E* 2017E*

Group Adjusted EBITDA margin % Group Revenues

Revenues from start-ups and companies in significant restructuring Mature Revenues

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

EUR 300m hybrid bond (of which EUR 150m tap

in July 2014 at 5% yield to call date (YTC))

non-dilutive bond with perpetual maturity,

callable at par by Eurofins in Jan 2020

interest: fixed coupon of 7.00%* until first call,

Euribor 3m + 818 bp thereafter if not called Hybrid OBSAAR

issued June 2010 maturity: EUR 176m across June 2015, 2016, 2017

Solid Balance Sheet

3.5 x

Net Debt/ LTM Adjusted

EBITDA Dec’13 Jun’14 2.07 x Maximum

Net Debt (EUR m)

386.8

36

Net Debt calculation Short-term borrowings

+ Long-term borrowings

• Cash & cash equivalents

= NET DEBT

Total Equity (EUR m) EUR 170m issued in July 2011 5-7 year maturity; mid-swap or Euribor 6m +

spread of 180-220 bp respectively Schuldschein 1.76 x 485.7 404.3

Cash + cash

equivalents (EUR m) 297.3 378.4 394.7

EUR 300m Eurobond issued in November 2013 Five-year maturity (Nov 2018) at an annual

interest of 3.125% Eurobond

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

lower effective cost of hybrid capital as second tranche was issued at lower YTC

*

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

2.08 x 1.86 x 1.94 x 2.07 x 0.00 x 0.50 x 1.00 x 1.50 x 2.00 x 2.50 x 3.00 x 3.50 x H1 2011 H1 2012 H1 2013 H1 2014 37

High Degree of Financial Flexibility

37 Net Debt/ LTM Adjusted EBITDA: max 3.5x

• Debt ratios remain well below covenant limits*

despite EUR 147m** cash invested in the business in H1 2014 (EUR 215m cash in 2013). Largely capex and acquisitions which did not fully contribute yet in H1 2014.

• Large financial flexibility with fairly long debt

maturity

OBSAAR issued in 2010; avg. maturity 2016 Schuldschein issued in 2011; avg. maturity 2017 Hybrid capital of EUR 300m; perpetual, callable 2020 EUR 300m Eurobond issued in 2013; maturing 2018 Extension and renewal of credit facilities

• Continued profitability improvement means that

key debt ratios have remained stable despite an increase in absolute amount in Net Debt to EUR 486m from EUR 387m in December 2013.

Substantial headroom in the balance sheet

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

* NB: Gearing covenant no longer applicable ** EUR 147m cash investments = EUR 56.9m capital expenditures + EUR 72.1m in acquisitions + EUR 18m one-off restructuring costs and temporary losses 37

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

EUR 864m of gross senior debt as of 30 June 2014 (net debt of EUR 485.7m) More than 95% of senior debt located in Eurofins Scientific SE (holding level) Main facilities in Eurofins Scientific SE: OBSAAR bonds (issued in June 2010) :

EUR 176m

Schuldschein (issued in July 2011) :

EUR 170m

Eurobond (issued in November 2013) :

EUR 300m

Bilateral RCF (drawn):

EUR 188m

EUR 25m of bank borrowings are secured over buildings and assets (in

subsidiaries)

In addition, EUR 300m Hybrid bond (considered equity under IFRS), non-

dilutive bond with perpetual maturity, callable at par by Eurofins in Jan 2020

Financing facility overview as of 30 June 2014

38

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

55.0 133.1 58.7 58.7 58.7 108.0 62.0 300.0

0.0 50.0 100.0 150.0 200.0 250.0 300.0 350.0 400.0 450.0 500.0 2015 2016 2017 2018

Bilateral credit lines (drawn) OBSAAR Schuldschein Eurobond

Maturity profile of senior debt at Holding level as of 30 June 2014

For private use only – Strictly confidential

Senior debt in Eurofins Scientific SE (EURm)

221.7 39 495.1

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Tangible Commitment from Internal Stakeholders

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

40

In July 2014, Eurofins issued

118,820 warrants exclusively to its leaders

Exercise Price €281.58 Purchase Price €18.15 Break-even Price €299.73

(in the money starting at €300)

The warrants are not listed but

gives access to new shares in Eurofins Scientific. The warrants are exercisable starting 01 July 2018, and valid for 10 years.

Eurofins will have the right to

accelerate the exercise of the warrants from July 2018 onwards if the share price is above €506.84 (i.e. 180% of exercise price)

Upside/Downside for warrant holders capital gain could be capped if exercise acceleration is triggered by the company

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

41

Food safety & contamination issues New regulations (e.g. FSMA, REACH) Outsourcing trend Risks due to globalisation of trade Vulnerability of global brands Scientific developments (e.g. GMOs,

Biologics…. ) + new testing methods

Outlook: becoming the world leader in the bioanalytical testing market

Unique technological portfolio of over

100,000 methods

Volume scale advantage &

Competence Centres

Focus on running labs Global network of standardised labs Experience in integrating value adding

acquisitions

Recurring revenues with high switching

costs and high barriers to entry

+

Key Success Factors Sustainable Market Growth Drivers

Eurofins’ unique position in a young, fast growing and fragmented market should lead to long term, sustainable profitability

= Solid Outlook

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

42

Introduction Market & Strategic Positioning Finance & Outlook Transaction Overview Summary Appendix

Contents

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Terms & Conditions of the contemplated bond issue Issuer:

Eurofins Scientific S.E.

Issue Rating:

Not rated

Issue Size:

EUR [300 m] minimum

Currency

EUR

Maturity

[7] years

Denomination:

EUR100k+1k

Listing:

Luxembourg Stock Exchange

Type:

Senior Unsecured

Documentation:

Standalone / Change of Control / Make Whole / Clean-Up Call

Global Coordinator:

HSBC

Joint Bookrunners:

BNP Paribas / HSBC / SG CIB

For private use only – Strictly confidential

43

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

44

Introduction Market & Strategic Positioning Finance & Outlook Transaction Overview Summary Appendix

Contents

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

45

High-growth, non-cyclical markets driven by secular mega-trends Advancing globalisation but with very few global testing suppliers Fragmented competition & opportunities for consolidation Very recurring business; 8% - 12% historic organic growth High barriers to entry Best in class technology and quality give best brand protection

• No. 1 or 2 worldwide in most business lines

Strong international presence in 36 countries State-of-the-art laboratory infrastructure High switching costs for clients Good cash flow visibility Experienced multi-national leadership

Conclusion: our sustainable competitive advantage Track record of profitable growth – Strong ROCE and cash flow generation potential ROCE* of 14.7% and ROE** of 19.1% in 2013 despite significant future-orientated investments and one-off restructuring

costs

5-year CAGR: EPS 30.7%, Operating Cash Flow 23.0% Large potential to roll out business model in fast growing economies Following the last intense investment cycle (2006-2010), Eurofins is well-positioned to double in size and reach EUR

2bn in revenues by 2017 whilst maintaining leadership in multiple markets and improving profitability

*ROCE = EBITAS/Average Capital Employed over previous 4 quarters **ROE = Net Profit/Equity at the beginning of the year

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

46

Appendix / Back up slides

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

• 1: Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.
• 2: Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other

costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects

EUR million Adjusted Results 1 Separately disclosed items 2 Total Adjusted Results 1 Separately disclosed items 2 Total Revenues 643.5 643.5 570.3 570.3 Operating costs, net

• 534.5
• 18.0
• 552.5
• 477.2
• 14.8
• 492.0

EBITDA 109.0

• 18.0

91.0 93.1

• 14.8

78.2 Depreciation and amortisation

• 32.7
• 5.0
• 37.7
• 26.9
• 4.5
• 31.4

EBITAS 76.3

• 23.0

53.2 66.2

• 19.4

46.8 Non-cash stock option charges and acquisition-related expenses, net

• 7.1
• 7.1
• 5.3
• 5.3

EBIT 76.3

• 30.2

46.1 66.2

• 24.7

41.5 Finance income 1.1 1.1 0.6 0.6 Finance costs

• 15.7
• 15.7
• 10.6
• 10.6

Share of profit of associates 0.3 0.3 0.2 0.2 Profit before income tax 62.0

• 30.2

31.8 56.4

• 24.7

31.8 Income tax expense

• 13.0

3.7

• 9.4
• 11.1

1.7

• 9.4

Net profit and loss for the period 48.9

• 26.5

22.4 45.4

• 23.0

22.4 Attributable to: Equity holders of the Company 48.9

• 26.4

22.6 45.2

• 22.7

22.5 Non-controlling interests 0.0

• 0.1
• 0.1

0.2

• 0.3
• 0.1

Source: Eurofins H1 2014 Results H1 2014 H1 2013

Consolidated Income Statement HY 2014 vs HY 2013

47

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Consolidated Balance Sheet HY 2014 vs HY 2013

EUR million H1 2014 H1 2013 EUR million H1 2014 H1 2013 Property, plant and equipment 279.8 231.1 Total shareholders' equity 404.3 360.3 Goodwill 497.6 439.0 Other intangible assets 108.9 75.2 Borrowings 790.9 438.1 Others 52.7 47.2 Others 103.1 91.6 Total non-current assets 939.0 792.5 Total non-current liabilities 893.9 529.7 Inventories 23.7 19.9 Borrowings 73.2 60.9 Trade accounts receivable 289.9 251.2 Trade accounts payable 94.8 77.6 Cash and cash equivalents 378.4 117.5 Others 231.7 203.3 Others 62.5 46.2 Total current liabilities 399.7 341.8 Total current assets 754.4 434.7 Asset classified as held for sale 4.5 4.7 Total assets 1,697.9 1,231.8 Total liabilities 1,697.9 1,231.8 Source: Eurofins H1 2014 Results

48

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Source: Eurofins H1 2014 Results

EUR million H1 2014 H1 2013 Cash flows from operating activities Profit before income taxes 31.8 31.8 Adjustments for: Depreciation and amortisation 37.7 31.4 Change in net working capital

• 27.2
• 5.4

Income tax paid

• 14.1
• 14.6

Others 19.1 11.5 Net cash provided by operating activities 47.4 54.7 Cash flows from investing activities Acquisition of subsidiaries, net of cash acquired

• 72.1
• 57.3

Purchase of property, plant and equipment

• 44.9
• 34.9

Purchase, capitalisation of intangible assets

• 12.6
• 8.3

Procees from sale of property, plant and equipment 0.5 0.3 Change in investments and financial assets, net

• 1.4
• 1.4

Dividends by Associates 0.1 0.0 Interest received 1.1 0.6 Net cash used in investing activities

• 129.3
• 100.9

Cash flows from financing activities Proceeds from issuance of share capital 1.7 5.2 Proceeds from borrowings 188.4 81.4 Repayments of borrowings

• 12.2
• 29.0

Change in hybrid capital

• 9.0

Dividends to shareholders and non-controlling interests 0.0 Earnings paid to hybrid capital investors

• 10.5
• 9.7

Interest paid

• 6.4
• 7.7

Others 0.1 0.3 Net cash provided by financing activities 161.1 31.4 Net effect of currency translation on cash and cash equivalents and bank

• verdrafts
• 0.4
• 1.6

Net increase (decrease) in cash and cash equivalents less bank overdrafts 78.9

• 16.5

Cash and cash equivalents less bank overdrafts at beginning of period 293.3 122.2 Cash and cash equivalents less bank overdrafts at end of period 372.2 105.8

Consolidated Cashflow Statement HY 2014 vs HY 2013

49

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

• 1: Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.
• 2: Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other

costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects

EUR million Adjusted Results 1 Separately disclosed items 2 Total Adjusted Results Separately disclosed items Total Revenues 1,225.6 1,225.6 1,044.0 1,044.0 Operating costs, net

• 1,006.3
• 30.2
• 1,036.5
• 867.5
• 15.3
• 882.7

EBITDA 219.3

• 30.2

189.1 176.5

• 15.3

161.2 Depreciation and amortisation

• 57.4
• 9.5
• 66.9
• 45.4
• 9.5
• 54.8

EBITAS 161.9

• 39.7

122.2 131.1

• 24.7

106.4 Non-cash stock option charges and acquisition-related expenses, net

• 10.0
• 10.0
• 5.2
• 5.2

EBIT 161.9

• 49.7

112.2 131.1

• 29.9

101.2 Finance income 1.1 1.1 1.5 1.5 Finance costs

• 24.6
• 24.6
• 21.2
• 21.2

Share of profit of associates 0.3 0.3 0.2 0.2 Profit before income tax 138.7

• 49.7

89.1 111.6

• 29.9

81.7 Income tax expense

• 22.0

4.9

• 17.2
• 19.8

2.0

• 17.8

Net profit and loss for the period 116.7

• 44.8

71.9 91.8

• 27.9

63.9 Attributable to: Equity holders of the Company 116.8

• 44.6

72.2 91.4

• 25.4

65.9 Non-controlling interests

• 0.1
• 0.2
• 0.3

0.4

• 2.5
• 2.0

Source: Eurofins 2013 Annual Report 2013 2012

Consolidated Income Statement FY 2013 vs FY 2012

50

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Consolidated Balance Sheet FY 2013 vs FY 2012

EUR million 2013 2012 Restated EUR million 2013 2012 Restated Property, plant and equipment 251.1 209.3 Total shareholders' equity 394.7 372.0 Goodwill 456.4 402.7 Other intangible assets 86.4 69.0 Borrowings 666.9 383.0 Others 54.2 43.8 Others 96.7 88.5 Total non-current assets 848.0 724.8 Total non-current liabilities 763.6 471.6 Inventories 20.1 13.9 Borrowings 17.2 52.1 Trade accounts receivable 272.7 247.9 Trade accounts payable 101.0 77.8 Cash and cash equivalents 297.3 134.3 Others 220.5 187.1 Others 54.5 37.2 Total current liabilities 338.7 317.0 Total current assets 644.5 433.2 Asset classified as held for sale 4.4 2.5 Total assets 1,497.0 1,160.5 Total liabilities 1,497.0 1,160.5 Source: Eurofins 2013 Annual Report

51

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Source: Eurofins 2013 Annual Report

Consolidated Cashflow Statement FY 2013 vs FY 2012

52

EUR million 2013 2012 Cash flows from operating activities Profit before income taxes 89.1 81.7 Adjustments for: Depreciation and amortisation 66.9 54.8 Change in net working capital 13.8

• 11.0

Income tax paid

• 30.5
• 12.9

Others 30.1 21.6 Net cash provided by operating activities 169.3 134.2 Cash flows from investing activities Acquisition of subsidiaries, net of cash acquired

• 87.4
• 79.3

Purchase of property, plant and equipment

• 79.2
• 58.4

Purchase, capitalisation of intangible assets

• 20.3
• 13.3

Procees from sale of property, plant and equipment 0.8 7.1 Change in investments and financial assets, net

• 4.0
• 1.9

Interest received 1.1 1.5 Net cash used in investing activities

• 189.0
• 144.3

Cash flows from financing activities Proceeds from issuance of share capital 8.0 24.4 Proceeds from borrowings 325.3 11.7 Repayments of borrowings

• 83.7
• 32.7

Change in hybrid capital

• 9.1

0.0 Dividends to shareholders and non-controlling interests

• 15.5
• 12.1

Earnings paid to hybrid capital investors

• 9.7
• 12.1

Interest paid

• 21.4
• 19.9

Net cash provided by financing activities 194.0

• 40.7

Net effect of currency translation on cash and cash equivalents and bank

• verdrafts
• 3.2
• 0.8

Net increase (decrease) in cash and cash equivalents less bank overdrafts 171.1

• 51.5

Cash and cash equivalents less bank overdrafts at beginning of period 122.2 173.7 Cash and cash equivalents less bank overdrafts at end of period 293.3 122.2

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Eurofins has vastly outperformed the market since its IPO and each of its 3 equity offerings (based on share price of EUR 212.05 as of 31 December 2014)

1997 € 5m 1998 rights issue € 6m

SPO 1

1999 rights issue € 7m

SPO 2

2000 SPO € 38.5m

SPO 3

Eurofins: +11,484% (32% CAGR)

CAC 40: +54% (3% CAGR) SBF 120: +78% (3% CAGR) S&P 500: +135% (5% CAGR)

Eurofins: +2,593% (23% CAGR) CAC 40: +20% (1% CAGR) SBF 120: +39% (2% CAGR) S&P 500: +93% (4% CAGR) Eurofins: +2,670% (25% CAGR) CAC 40: -9% (-1% CAGR) SBF 120: 5% (0% CAGR) S&P 500: +59% (3% CAGR) Eurofins: +393% (12% CAGR) CAC 40: -32% (-3% CAGR) SBF 120: -20% (-2% CAGR) S&P 500: +49% (3% CAGR) Eurofins: +1166% (29% CAGR) CAC 40: +12% (1% CAGR) SBF 120: +24% (2% CAGR) S&P 500: +70% (5% CAGR)

10 years Since SPO 2 Since SPO 1 Since IPO Since SPO 3 2 years

Eurofins: +73% (32% CAGR) CAC 40: 17% (8% CAGR) SBF 120: 20% (10% CAGR) S&P 500: +44% (20% CAGR)

5 years

Eurofins: +455% (41% CAGR) CAC 40: 9% (2% CAGR) SBF 120: 18% (3% CAGR) S&P 500: +85% (13% CAGR)

Total equity raised in 4 offerings: only EUR 56m

53

IPO

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

Eurofins has generated comparable organic growth to its larger peers which have deeper footprint in fast-growing emerging markets and in cyclical areas

Source: Eurofins, Company websites

In spite of its lower cyclicality, Eurofins generates comparable organic growth to its larger peers in each cycle, and higher growth when the economy slows

H1 2014

TICS ex ERF = SGS, Intertek, Bureau Veritas * Includes 2% organic growth consensus estimate for Bureau Veritas for H1 2014

54

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

We have built a hard-to-replicate world-class infrastructure

Eurofins has been consistently investing more than its peers

Source: Eurofins, Company reports

0% 10% 20% 30% 40% 50% 60% 70% 80% 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 00-'04 05-'08 09-'10 2010 2011 2012 2013

Excess Investment Capex to Sales

ERF TICS ex ERF Excess investment

TICS ex ERF = SGS, Intertek, Bureau Veritas

55

Source presentation EDR: 1-C-IR-PRE-01187643 Source modification date: 07/08/2014

56

Post acquisition and integration into Eurofins, both sales and profits increase significantly

Illustration

0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

Annual Sales / million Acquired by Eurofins CAGR 19% EBITA margin in % of sales <8% >20%

Growth drivers post acquisition:

1)

Sales increase through cross selling of Eurofins lab specialities internationally

2)

Cost reduction – focus on most frequently performed tests

Frequency (e.g. no. of tests per day)

• No. of tests offered

100 Prior to acquisition 50% 50% % of employees performing tests Can be subcontracted to specialised Eurofins laboratories after acquisition 400

Focus and scale drive profitability Actual example of an acquired lab:

100 50 500

Company A

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay